File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Duration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of randomised controlled trials

TitleDuration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of randomised controlled trials
Other TitlesDuration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of randomized controlled trials
Authors
Issue Date2016
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
The 21st Medical Research Conference (MRC 2016), Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 16 June 2016. In Hong Kong Medical Journal, 2016, v. 22 n. suppl. 1, p. 21, abstract no. 24 How to Cite?
AbstractINTRODUCTION: Patients are recommended for 6 to 12 months of dual antiplatelet therapy (DAPT) after drugeluting stents (DES) implantation. The optimal duration of DAPT has been debated. Therefore, this metaanalysis was conducted to evaluate safety and efficacy of different DAPT durations after DES implantation. METHODS: We searched the literature using MEDLINE, Scopus, EMBASE, ISI Web of Science, Cochrane Library, ClinicalTrials.gov, and recent conference proceedings. We included trials randomising patients to receive different durations of DAPT after DES implantation. Data were analysed with RevMan. RESULTS: Eleven randomised controlled trials with 23 559 patients were included for analysis with four trials comparing extended DAPT versus 12-month regimen and seven trials comparing short-term DAPT versus 12-month regimen. Compared to 12-month DAPT treatment, extended DAPT was significantly associated with lower frequency of myocardial infarctions (odds ratio [OR]=0.36; 95% confidence interval [CI], 0.24-0.55; P < 0.00001) but the risks of major bleeding (OR=1.54; 95% CI, 1.22-1.96) and all-cause mortality (OR=1.43; 95% CI, 1.14-1.81) were substantially increased. There was no significant difference in preventing stroke, cardiac mortality, and repeat revascularisation. Compared to shortterm DAPT, 12-month DAPT was associated with increased major bleeds (OR=1.98; 95% CI, 1.26-3.11). However, no significant alteration was found in the risk of other primary outcomes. CONCLUSION: Extended DAPT beyond 12 months yields benefits in reducing myocardial infarction and stent thrombosis, but it increases risk of bleeding and all-cause mortality. Discontinuation of DAPT before 12 months decreases number of major bleeds with no apparent difference in other primary endpoints.
Persistent Identifierhttp://hdl.handle.net/10722/232474
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorFei, Y-
dc.contributor.authorTsoi, MF-
dc.contributor.authorCheung, TT-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2016-09-20T05:30:15Z-
dc.date.available2016-09-20T05:30:15Z-
dc.date.issued2016-
dc.identifier.citationThe 21st Medical Research Conference (MRC 2016), Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 16 June 2016. In Hong Kong Medical Journal, 2016, v. 22 n. suppl. 1, p. 21, abstract no. 24-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/232474-
dc.description.abstractINTRODUCTION: Patients are recommended for 6 to 12 months of dual antiplatelet therapy (DAPT) after drugeluting stents (DES) implantation. The optimal duration of DAPT has been debated. Therefore, this metaanalysis was conducted to evaluate safety and efficacy of different DAPT durations after DES implantation. METHODS: We searched the literature using MEDLINE, Scopus, EMBASE, ISI Web of Science, Cochrane Library, ClinicalTrials.gov, and recent conference proceedings. We included trials randomising patients to receive different durations of DAPT after DES implantation. Data were analysed with RevMan. RESULTS: Eleven randomised controlled trials with 23 559 patients were included for analysis with four trials comparing extended DAPT versus 12-month regimen and seven trials comparing short-term DAPT versus 12-month regimen. Compared to 12-month DAPT treatment, extended DAPT was significantly associated with lower frequency of myocardial infarctions (odds ratio [OR]=0.36; 95% confidence interval [CI], 0.24-0.55; P < 0.00001) but the risks of major bleeding (OR=1.54; 95% CI, 1.22-1.96) and all-cause mortality (OR=1.43; 95% CI, 1.14-1.81) were substantially increased. There was no significant difference in preventing stroke, cardiac mortality, and repeat revascularisation. Compared to shortterm DAPT, 12-month DAPT was associated with increased major bleeds (OR=1.98; 95% CI, 1.26-3.11). However, no significant alteration was found in the risk of other primary outcomes. CONCLUSION: Extended DAPT beyond 12 months yields benefits in reducing myocardial infarction and stent thrombosis, but it increases risk of bleeding and all-cause mortality. Discontinuation of DAPT before 12 months decreases number of major bleeds with no apparent difference in other primary endpoints.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleDuration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of randomised controlled trials-
dc.title.alternativeDuration of dual antiplatelet therapy after drug-eluting stent implantation: meta-analysis of randomized controlled trials-
dc.typeConference_Paper-
dc.identifier.emailCheung, TT: tcheungt@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, TT=rp01682-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.hkuros265898-
dc.identifier.volume22-
dc.identifier.issuesuppl. 1-
dc.identifier.spage21, abstract no. 24-
dc.identifier.epage21, abstract no. 24-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats